Migraine Breakthrough: Not So Fast

Migraine Breakthrough: Not So Fast

Submitted by CP Staff on June 6, 2018 - 9:49pm
Source: 
Forbes
News Tags: 
Amgen
Novartis
Aimovig
migraines
adults
monoclonal antibodies
Headline: 
Migraine Breakthrough: Not So Fast
snippet: 
Two weeks ago the Food and Drug Administration (FDA) approved the monoclonal antibody erenumab (brand name Aimovig, marketed by Amgen and Novartis) for the prevention of migraine in adult patients.

Do Not Allow Advertisers to Use My Personal information